v3.25.4
Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended 18 Months Ended
Jan. 31, 2026
USD ($)
Oct. 31, 2025
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Jul. 31, 2024
USD ($)
candidate
aqua_facility
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Dec. 31, 2026
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2025
USD ($)
May 31, 2025
USD ($)
Apr. 30, 2024
candidate
Feb. 29, 2024
USD ($)
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
candidate
Feb. 28, 2023
USD ($)
candidate
Business Combination [Line Items]                                        
Research and development                       $ 15,789.0 $ 17,938.0 $ 30,531.0            
Property, plant and equipment, net       $ 23,779.0               25,316.0 23,779.0 23,051.0 $ 25,316.0          
Other intangibles, net       16,370.0               26,681.0 16,370.0   26,681.0          
Elanco Animal Health Incorporated Aqua Business                                        
Business Combination [Line Items]                                        
Cash paid for acquisition of business           $ 1,300.0                            
Aqua manufacturing facilities | aqua_facility           2                            
Dr. Falk Pharma                                        
Business Combination [Line Items]                                        
Research and development                       150.0                
Orion                                        
Business Combination [Line Items]                                        
Eligible future contingent development-related payments (up to)           $ 30.0                            
Aggregate, regulatory milestones payments, maximum           625.0                            
Sales milestone payments           $ 975.0                            
Alteogen Inc.                                        
Business Combination [Line Items]                                        
Aggregate, regulatory milestones payments, maximum                                   $ 51.0    
Sales milestone payments                                   1,000.0    
Probable contingent payments                       890.0                
Alteogen Inc. | Keytruda Qlex | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Combination [Line Items]                                        
Collaborative arrangement, rights and obligations, liabilities resulting from milestone payments                       930.0     930.0     $ 40.0    
Other intangibles, net                       930.0     930.0          
Regulatory milestone payments                       40.0                
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Combination [Line Items]                                        
Research and development                       524.0 351.0 5,549.0            
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate                                     3  
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Combination [Line Items]                                        
Eligible future contingent development-related payments (up to)                                     $ 540.0  
Aggregate, regulatory milestones payments, maximum                                     1,500.0  
Sales milestone payments                                     $ 3,100.0  
Number of antibody drug conjugates | candidate                                       7
Upfront payment made to collaborative partner                                       $ 175.0
Number of antibody drug conjugates terminated | candidate                                 1   2  
Number of exercised license option antibody drug conjugates | candidate           1                            
Number of licensed antibody drug conjugates | candidate           3                            
Number of unexercised license option antibody drug conjugates | candidate           1                            
Payment resulting from the license option exercise           $ 38.0                            
Contingent developmental milestone payments                       20.0                
Stock investment in counterparty                 $ 100.0                      
Cidara Therapeutics, Inc. | Forecast                                        
Business Combination [Line Items]                                        
Research and development                     $ 9,000.0                  
Cidara Therapeutics, Inc. | Subsequent Event                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition $ 9,200.0                                      
Verona Pharma plc                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition   $ 10,400.0                                    
Asset acquisition, intangible assets   12,100.0                                    
Cash recorded for asset acquisition   495.0                                    
Asset acquisition, inventories   522.0                                    
Fair value step up   498.0                                    
Asset acquisition, deferred tax liabilities   2,700.0                                    
Other net liabilities recorded for asset acquisition   $ 51.0                                    
Asset acquisition, finite-lived intangible asset, useful life   9 years                                    
sac-TMT | Forecast                                        
Business Combination [Line Items]                                        
Compensation earned on arrangement (up to)                   $ 700.0                    
HRS-5346, Jiangsu Hengrui Pharmaceuticals Co., Ltd.                                        
Business Combination [Line Items]                                        
Research and development                       200.0                
Jiangsu Hengrui Pharmaceuticals Co., Ltd.                                        
Business Combination [Line Items]                                        
Future contingent developmental milestone payments (up to)                               $ 92.5        
Future regulatory milestone payments (up to)                               177.5        
Maximum aggregate sales-based milestone payments                               $ 1,500.0        
WuXi Vaccines' facility                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition     $ 437.0                                  
WuXi Vaccines' facility | Asset under Construction                                        
Business Combination [Line Items]                                        
Property, plant and equipment, net     $ 759.0                                  
LM-299, LaNova Medicines Ltd                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition       588.0                                
Research and development                       300.0                
Future contingent developmental milestone payments (up to)       140.0                 140.0              
Future regulatory milestone payments (up to)       860.0                 860.0              
Maximum aggregate sales-based milestone payments       1,400.0                 1,400.0              
HS-10535 Hansoh Pharma                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition       112.0                                
Future contingent developmental milestone payments (up to)       115.0                 115.0              
Future regulatory milestone payments (up to)       315.0                 315.0              
Maximum aggregate sales-based milestone payments       $ 1,470.0                 1,470.0              
Developmental milestone payment triggered and paid                       15.0                
CN201, Curon Biopharmaceutical                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition         $ 700.0                              
Research and development                         750.0              
Future contingent developmental milestone payments (up to)         300.0                              
Future regulatory milestone payments (up to)         300.0                              
CN201, Curon Biopharmaceutical | Third-Party                                        
Business Combination [Line Items]                                        
Aggregate contingent developmental, regulatory, and sales-based-related payments         $ 128.0                              
Eyebiotech Limited                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition           1,200.0                            
Research and development                         1,350.0              
Future contingent developmental milestone payments (up to)           1,000.0                            
Future regulatory milestone payments (up to)           200.0                            
Maximum aggregate sales-based milestone payments           500.0                            
Developmental milestone payment triggered and paid                       $ 100.0 100.0   $ 200.0          
Transaction costs           207.0                            
Net assets acquired           $ 21.0                            
Harpoon Therapeutics, Inc.                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition             $ 765.0                          
Research and development                         $ 656.0              
Transaction costs             56.0                          
Net assets acquired             $ 165.0                          
Prometheus Biosciences, Inc.                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition               $ 11,000.0                        
Research and development                           10,200.0            
Cash recorded for asset acquisition               368.0                        
Other net liabilities recorded for asset acquisition               5.0                        
Net assets acquired               877.0                        
Consideration transferred, to settle share-based equity awards               1,200.0                        
Consideration transferred, to settle equity awards, unvested               700.0                        
Investments recorded for asset acquisition               296.0                        
Asset acquisition, deferred tax assets               $ 218.0                        
Imago BioSciences, Inc.                                        
Business Combination [Line Items]                                        
Consideration transferred, asset acquisition                 1,350.0                      
Research and development                           $ 1,200.0            
Transaction costs                 60.0                      
Net assets acquired                 $ 219.0